Funding opportunities for COVID-19 research available to investigators

Research Development and the Research Concierge Service at Penn State College of Medicine have developed a list of funding opportunities for investigators interested in research projects related to COVID-19.

The National Science Foundation, National Institutes of Health, Centers for Disease Control and other institutions are supporting research from a variety of disciplines to address the COVID-19 pandemic.

Note regarding human subjects research

In order to reduce any additional personal contact between individuals, certain guidelines are in place for clinical research. See details on the University’s requirements for human subjects research here.

University funding

• Added April 7, 2020: Institute for Computational and Data Sciences’ Explore Grants – note that this opportunity focuses on supporting Penn State researchers using Penn State’s supercomputing system (ICDS-ACI), collaboration with the ICDS RISE team of computational experts and assistance accessing the rapidly growing stores of COVID-19 data beyond Penn State (rolling deadline)

Department of Defense

• Updated March 2, 2021: Medical CBRN Defense Consortium List of Solicitations
• Added April 23, 2020: Army Medical Research and Development Command New Products and Ideas (NPI)
• Added April 23, 2020: Joint Acquisition Task Force (JATF) COVID-19
• Added April 15, 2020: Army Applications Laboratory

Department of Health and Human Services

• Updated March 3, 2021: Biomedical Advanced Research and Development Authority (BARDA) – BAA-18-100-SOL-00003 Broad Agency Announcement (BAA) – COVID-19 – note only submissions in support of COVID-19 research are being reviewed by BARDA at this time (deadline Oct. 31, 2021)

National Institutes of Health (NIH)

• NEW Added April 20, 2021: RFA-AA-21-003 SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed). (letter of intent deadline July 17, 2021)
• NEW Added April 20, 2021: RFA-AA-21-004 SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed). (letter of intent deadline July 17, 2021)
• NEW Added April 20, 2021: Notice of Special Interest (NOSI) The National Institute on Drug Abuse (NIDA) announced the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunities: PA-18-935 and PA-20-272. (rolling deadlines through March 31, 2022)
• NEW Added April 20, 2021: RFA-OD-21-008 Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional). This Testing Research Projects FOA will support research teams with established community-engaged partnerships to address the scientific objectives described herein. (deadline July 7, 2021)
• NEW Added April 20, 2021: RFA-OD-21-009 Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional). This SEBI research FOA will support research teams with established community engaged partnerships to address the scientific objectives described herein. (deadline July 7, 2021)
• NEW Added April 16, 2021: NOT-OD-21-103 Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19. Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (Emergency Supplement – Clinical Trial Optional). The NIH Office of the Director (OD) is issuing this NOSI to request competitive revision applications addressing the objectives outlined in the NOSI. (deadline May 24, 2021)
• NEW Added April 16, 2021: NOT-OD-21-101 – Notice of Special Interest (NOSI): Administrative Supplements for Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) Phase I Projects to Address Vaccine Hesitancy and Uptake (deadline May 10, 2021)
• NEW Added April 16, 2021: Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional). The NIH intends to commit $24 Million over 2 years to fund approximately 16 awards. (deadline July 7, 2021
• NEW Added April 16, 2021: Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional). (deadline July 7, 2021)
• NEW Added April 16, 2021: NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. In order to rapidly improve our understanding of the risks, prevalence and available control measures for SARS-CoV-2 in substance using and/or HIV-affected populations, NIDA is encouraging the submission of applications for Administrative Supplements or Competitive Revisions to active grants to address several specific research areas of interest outlined in this NOSI.(Rolling deadlines through March 31, 2022)
• Added April 13, 2021: RFA-AG-21-035 Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed) (letter of intent deadline May 9, 2021)
• Added April 8, 2021: NOT-OD-21-064 Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase II) (deadline April 30, 2021) Notes: The National Institutes of Health (NIH) is issuing this Notice to alert the community about four upcoming Funding Opportunity Announcements (FOAs) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative to solicit intervention research on COVID-19 diagnostic testing among underserved and vulnerable populations. The FOAs are expected to be published in April, and NIH acceptance of applications will depend on the time frame outlined in each opportunity announcement, but will be no later than July 31. The FOAs will include two Requests for Applications (RFAs) and two Notices of Special Interest (NOSIs). The goal is to make awards as early as October 2021.
• Added April 8, 2021: PAR-21-213 Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed) (deadlines June 9 and Nov. 8, 2021)
• Added March 23, 2020: RFA-AI-20-028 Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
• Added March 15, 2021: NOT-GM-21-032 Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy (deadline April 30, 2021)
• Added March 3, 2021: NOT-AG-21-016 Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration (rolling deadlines from June 5, 2021, to May 8, 2023)
• Added March 3, 2021: NOT-GM-21-019 Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (rolling deadlines through Dec. 16, 2021)
• Added Feb. 19, 2021: Notice of Special Interest (NOSI) – NOT-AG-21-015: Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19) (deadline May 8, 2023)
• Added Feb. 19, 2021: Notice of Special Interest (NOSI) – NOT-DA-21-011: Effects of smoking and vaping on the risk and outcome of COVID-19 infection (deadline Sept. 8, 2024)
• Added Feb. 19, 2021: Notice of Special Interest (NOSI) – NOT-DA-21-018: Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders (deadline Sept. 8, 2024)
• Notice of Special Interest (NOSI) – NOT-DE-21-001: NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19) (deadline May 8, 2023)
• Added Nov. 8, 2020: NOT-DA-20-084 – Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection (deadline Sept. 8, 2024)
• Added Oct. 26, 2020: NOT-HD-20-031 – Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic (deadline May 8, 2023)
• Added Aug. 11, 2020: Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required) (rolling deadline and review)
• Added Aug. 3, 2020: PAR-20-256 (NIAID) – Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act.” (deadline July 8, 2021)
• Added July 10, 2020: NOT-OD-20-129 – Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project (deadline July 12, 2021) Note: Applications for this initiative must be submitted electronically using one of the following target opportunities or their subsequent reissued equivalents: PA-18-591 or PA-18-935.
• Added July 10, 2020: NOT-AI-20-059 – NIAID Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Applications in response to this NOSI must be submitted using the following targeted funding opportunity or subsequently reissued equivalent: PA-20-135. (deadline July 2, 2021)
• Added June 22, 2020: NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) (multiple deadlines through 2021)
• Updated May 19, 2020: NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (deadline Sept. 8, 2021)
• Added May 4, 2020: National Institute of Biomedical Imaging and Bioengineering Point-of-Care Technology Research Network Fast-Track Program for COVID-19 Test Development and Distribution: Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing (NIBIB) (rolling deadline)
• Updated May 1, 2020: NOT-DK-20-026 Notice of Additional Activity Code Accepted for “NOT-DK-20-018, Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK”
• Added May 1, 2020: NOT-TR-20-018 Notice of Change in Eligibility and Activity Codes for NOT-TR-20-011, Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
• Added April 27, 2020: NOT-AG-20-022 Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (deadline May 1, 2021)
• Added April 27, 2020: NOT-CA-20-043 Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)
• Added April 27, 2020: NOT-DC-20-006 Notice of Eligibility Change for NIDCD Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19
• Added April 27, 2020: NOT-ES-20-015 Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (deadline May 4, 2021)
• Added April 27, 2020: NOT-ES-20-020 Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
• Added April 27, 2020: NOT-MD-20-019 Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (deadline May 1, 2021)
• Added April 27, 2020: NOT-TR-20-017 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (deadline Jan. 26, 2022)
• Added April 27, 2020: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) (deadline Jan. 25, 2022)
• Added April 27, 2020: PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional) (deadline March 10, 2023)
• Updated April 7, 2020: NOT-TR-20-011 Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need (deadline July 10, 2021)

Resources

• Added March 26, 2020: Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding – includes a video update on common questions, FAQs on flexibilities for the research community, funding opportunities and more
• Added March 23, 2020: NIAID’s Multi-Pronged Response to the COVID-2019 Outbreak
• Added March 23, 2020: NIH Fogarty International Center Coronavirus news, funding and resources for global health researchers (resource)

National Science Foundation: RAPID Research on Coronavirus (COVID-19)

• Added March 27, 2020: NSF 20-065 Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
• Added March 23, 2020: NSF 20-052 Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (also see NSF 20-052 FAQs)
• Added March 23, 2020: NSF 20-055 Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

Resources

• NSF Supporting Research to Address Coronavirus Disease (blog)

Patient-Centered Outcomes Research Institute (PCORI)

• Added April 23, 2020: PCORI Funding Opportunities for COVID-19-Related Enhancements to Existing PCORI-Funded Projects (rolling deadline)

USAID

• Added March 23, 2020: 7200AA20RFA00007 Strategies To Prevent (STOP) Spillover RFI and Virtual Conference (3.23)

Foundations

Note: Investigators with interest in foundation funding should contact Corporate and Foundation Relations before proceeding with any application process.

• Added May 19, 2020: Draper Richards Kaplan Foundation Coronavirus Urgent Response Initiative (rolling deadline)

Other Funders

Note: Investigators with interest in corporate funding should contact Corporate and Foundation Relations before proceeding with any application process.

• Added Aug. 11, 2020: Social Science Research Council – Just Tech Covid-19 Rapid-Response Grants (rolling deadline)
• Added May 15, 2020: CETF and Rockefeller Philanthropy Advisors – COVID-19 Early Treatment Fund (rolling deadline)
• Added April 27, 2020: EdTech Hub, mEducation Alliance and Global Innovation Exchange Call for Ideas for EdTech Responses to Coronavirus (COVID-19) (rolling deadline)
• Added April 27, 2020: Rapidly Emerging Antiviral Drug Discovery Initiative (READDI)
• Added April 15, 2020: Allen Institute for AI COVID-19 Open Research Dataset Challenge (CORD-19)
• Added April 15, 2020: CoVent-19 Challenge: Innovate2Ventilate
• Added April 15, 2020: IBM: COVID-19 Call for Code
• Added April 15, 2020: XPRIZE Pandemic Alliance: Fight COVID-19
• Added April 13, 2020: Google Cloud Research Credits
• Added April 9, 2020: Emergent Ventures: Fast Funding for COVID-19 Science
• Added April 9, 2020: Joint European Disruptive Initiative (JEDI) – Billion Molecules Against COVID-19 JEDI Grand Challenge
• Added April 8, 2020: Pfizer COVID-19-Related Grant Requests
• Added March 26, 2020: Amazon AWS Diagnostic Development Initiative (DDI)

Learn more

For details, contact the Research Concierge Service at researchconcierge@pennstatehealth.psu.edu.

If you're having trouble accessing this content, or would like it in another format, please email the Penn State College of Medicine web department.